ScreenerHero

DNA Ginkgo Bioworks Holdings, Inc.

NYSE · US · Healthcare · Biotechnology · ginkgo.bio
11.47USD-7.57%Mkt Cap: 772.39M $P/E: —

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell en…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap772.39M USD
Enterprise Value937.64M USD
Revenue (TTM)132.42M USD
Gross Profit123.18M USD
Net Income (TTM)-312.76M USD
Revenue/Share2.26 USD
Last Price11.47 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees485
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.28
PEG—
EV/EBITDA-3.58
EV/Revenue7.08
P/S6.31
P/B1.88
EPS (TTM)-4.19
EPS (Forward)-2.90
52W Range
5.37047% of range18.22
52W High18.22 USD
52W Low5.370 USD
Profitability
Gross Margin72.39%
Oper. Margin-284.99%
EBITDA Margin-197.57%
Profit Margin-183.81%
ROE-61.50%
ROA-27.93%
Growth
Revenue Growth-48.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-171.06M USD
CapEx (TTM)7.67M USD
FCF Margin-54.67%
FCF Yield-9.37%
Net Debt101.95M USD
Net Debt/EBITDA-0.39
Balance Sheet
Debt/Equity0.86
Current Ratio4.57
Quick Ratio4.33
Book Value/Sh6.60 USD
Cash/Share4.49 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:40
Split DateAug 20, 2024
Analyst Consensus
Rating—
Target (Mean)7.000 USD
Upside (mean)-39.0%
Target Range5.000 USD – 9.000 USD
5.000-39.0% to mean9.000
# Analysts2
Ownership
Shares Out.55.38M
Float49.88M
Insiders4.43%
Institutions73.73%
Short Interest
Short Ratio6.3d
Short % Float13.36%
Short % Out.10.64%
Shares Short7.17M
Short (prev mo.)5.60M
Technical
SMA 508.228 (+39.4%)
SMA 2008.356 (+37.3%)
Beta1.79
S&P 52W Chg16.45%
Avg Vol (30d)2.52M
Avg Vol (10d)3.57M
Technical Indicators
RSI (14)57.3
MACD1.4076
MACD Signal1.1197
MACD Hist.+0.2878
BB Upper14.82 USD
BB Middle9.806 USD
BB Lower4.788 USD
BB Width102.34%
ATR (14)1.446 USD
Vol Ratio (20d)2.16x